THERMALIN DIABETES, INC.

Basic Information

10000 Cedar Avenue
CLEVELAND, OH, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 802601570
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Chlorolog: Production Scaling and Testing of a Fast-Acting, Ultra-stable Insulin

    Amount: $4,469,515.00

    DESCRIPTION (provided by applicant): We seek to develop a novel insulin analog to enhance the safety and efficacy of insulin pump therapy with broad application to the Artificial Pancreas Project ( s ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Manipulating Aromaticity: characterization of an ultra-rapid insulin analog

    Amount: $601,274.00

    DESCRIPTION (provided by applicant): We seek to develop an ultra-fast insulin analog formulation for the treatment of diabetes mellitus. Ultra-fast pharmacokinetic/dynamic (PK/PD) promises to enable s ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. Optimized Receptor Binding Profile in an Ultra-Stable, Ultra-Rapid-Acting Insulin

    Amount: $622,539.00

    DESCRIPTION (provided by applicant): We seek to develop an ultra-fast, zinc-free insulin analog formulation for the treatment of diabetes mellitus. An ultra-fast pharmacokinetic-dynamic (PK/PD) profil ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Halogenated Insulin: a fast-acting, ultra stable analog.

    Amount: $392,091.00

    DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel rapid-acting insulin analog for the treatment of diabetes mellitus. Designated I ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. A Novel 'Zinc-Stapled' Long-Acting Insulin Analog

    Amount: $423,635.00

    DESCRIPTION (provided by applicant): A Phase 1 SBIR program of pre-clinical development is proposed focusing on a novel long-acting insulin analog for the basal treatment of diabetes mellitus. Designa ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Clinical Testing of an Insulin Analog

    Amount: $254,997.00

    DESCRIPTION (provided by applicant): The central goal of insulin replacement therapy in the treatment of Type 1 diabetes mellitus (T1DM) is tight control of blood glucose concentration. This Phase I ...

    STTR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government